^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    albumin-bound docetaxel (CPO100)

    i
    Other names: CPO100, docetaxel nanoparticle formulated with human albumin, DTX-HSA, CPO-100, HB1801
    Associations

    News

    Trials
    Company:
    CSPC Pharma
    Drug class:
    Tubulin inhibitor
    Related drugs:
    Associations

    News

    Trials
    19d
    CPO-100-US-101: Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=34, Terminated, Conjupro Biotherapeutics, Inc. | N=126 --> 34 | Active, not recruiting --> Terminated; Business Decision
    Enrollment change • Trial termination
    |
    albumin-bound docetaxel (CPO100)
    3ms
    A study on the treatment of advanced gastric/gastroesophageal junction adenocarcinoma with docetaxel for injection (albumin-bound type) combined with oxaliplatin and 5-FU/LV (ADOF) (ChiCTR2500112147)
    P=N/A, N=12, Not yet recruiting, Fujian Cancer Hospital; CSPC Zhongqi Pharmaceutical Technology Co., Ltd.
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR • HER-2 overexpression
    |
    5-fluorouracil • oxaliplatin • albumin-bound docetaxel (CPO100)
    8ms
    Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors (clinicaltrials.gov)
    P2, N=350, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Haiyitan (gumarontinib) • albumin-bound docetaxel (CPO100)
    8ms
    HB1801 Combined Treatment of HER2-positive Breast Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P2 trial
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • albumin-bound docetaxel (CPO100)
    9ms
    Glumetinib for MET Overexpression and/or Amplification in Advanced Gastric Cancer: A Phase II Clinical Study‌ (ChiCTR2500104368)
    P2, N=112, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New P2 trial
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    HER-2 positive • HER-2 expression • MET amplification • MET overexpression
    |
    albumin-bound paclitaxel • Haiyitan (gumarontinib) • albumin-bound docetaxel (CPO100)
    9ms
    A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P2 trial
    |
    docetaxel • albumin-bound docetaxel (CPO100)
    12ms
    Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors (clinicaltrials.gov)
    P2, N=350, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P2 trial
    |
    Haiyitan (gumarontinib) • albumin-bound docetaxel (CPO100)
    over1year
    A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer (clinicaltrials.gov)
    P3, N=630, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Enrolling by invitation --> Recruiting
    Enrollment status
    |
    albumin-bound docetaxel (CPO100)
    over1year
    A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer (clinicaltrials.gov)
    P3, N=630, Enrolling by invitation, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    albumin-bound docetaxel (CPO100)
    over1year
    CPO-100-US-101: Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=126, Active, not recruiting, Conjupro Biotherapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    albumin-bound docetaxel (CPO100)
    over1year
    A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=256, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P2 trial • Metastases
    |
    Haiyitan (gumarontinib) • albumin-bound docetaxel (CPO100)
    almost2years
    A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
    P3, N=142, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P3 trial • Metastases
    |
    albumin-bound docetaxel (CPO100)